Epstein Secrets

r executive positions with Quantanova and Scotia Holdings, plc. Prior to that, Dr. Dow was head of Global Drug Development with Hoffman-La Roche in Basel, Switzerland and previously was with Syntex Corporation for over 10 years in various senior positions in drug development. Dr. Dow holds a B.Sc. in

P, OM* • Growth factors, ctt(Npese Lumen Intim° [D.L-S P,FIT CAPITAL LLC EFTA_R1_01138815 EFTA02295541 Mechanism of Neointimal Thickening Medial SMC proliferation Lumen .Er-iclothelial cells Growth factors, ctfdlitits O° OO DACART CAPITAL Lac Intim° Adventitin EFTA_R1_01138816 EFTA02295542

r executive positions with Quantanova and Scotia Holdings, plc. Prior to that, Dr. Dow was head of Global Drug Development with Hoffman-La Roche in Basel, Switzerland and previously was with Syntex Corporation for over 10 years in various senior positions in drug development. Dr. Dow holds a B.Sc. in

IMIP Lumen Intima Adventitia Fibroblasts, fat cells, interstitial matrix DACART CAPITAL LLC7 EFTA00506120 Mechanism of Neointimal Thickening Medial SMC proliferation () 0 0 0 0 0 0 0 Endothelial cells Growth factors, cit6b%-- oc) 00 Lumen Intima Fibroblasts, fat cells, interstitial IMP

r executive positions with Quantanova and Scotia Holdings, plc. Prior to that, Dr. Dow was head of Global Drug Development with Hoffman-La Roche in Basel, Switzerland and previously was with Syntex Corporation for over 10 years in various senior positions in drug development. Dr. Dow holds a B.Sc. in

110 411•1. 411Mir Fibroblasts, fat cells, interstitial matrix Adventitia DACART CAPITAL LLC7 EFTA00506173 Mechanism of Neointimal Thickening Medial SMC proliferation Adventitia Fibroblasts, fat cells, intersti '- ' DACART CAP' JAL LLC: EFTA00506174 SMC migration and neointimal lesion developmen